Open Payments

LANGLEY PORTER PSYCHIATRIC HOSPITAL

Type
Teaching hospital
Where
San Francisco, CA
Medicare CCN
054144
Received
$73,663,874 in 2,931 records, 2022 ($3,838,229 general, $69,825,645 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment435$3,838,229
2022Research payment2,496$69,825,645

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC118$11,089,9192022
Genentech, Inc.179$9,999,5012022
Abbott Laboratories540$6,439,9072022
AstraZeneca Pharmaceuticals LP37$6,055,4412022
Janssen Research & Development, LLC135$3,466,6602022
F. Hoffmann-La Roche AG18$3,295,9352022
Eli Lilly and Company30$3,218,5332022
Celgene Corporation24$2,528,4032022
Novartis Pharmaceuticals Corporation24$2,223,5292022
PFIZER INC.72$1,812,7792022
Takeda Pharmaceuticals U.S.A., Inc.65$1,609,5282022
E.R. Squibb & Sons, L.L.C.42$1,550,8032022
Novo Nordisk AS3$1,505,3602022
Regeneron Pharmaceuticals, Inc.59$1,483,6492022
BioMarin Pharmaceutical Inc.27$1,247,1912022
ABBVIE INC.93$1,167,3902022
Gilead Sciences, Inc.36$1,115,0582022
Roche Products Limited45$828,5122022
Amgen Inc.26$770,9862022
AstraZeneca UK Limited10$692,7032022
Boston Scientific Corporation39$641,9812022
Alnylam Pharmaceuticals Inc.26$622,8132022
GE HEALTHCARE10$590,1482022
Stryker Corporation35$431,5182022
SEAGEN INC.105$416,1792022
Daiichi Sankyo Inc.21$409,7582022
Haemonetics Corporation21$319,9462022
TAIHO ONCOLOGY, INC.3$313,2692022
GENZYME CORPORATION29$303,8732022
Siemens Medical Solutions USA, Inc.16$300,4642022
JAZZ PHARMACEUTICALS INC.7$288,0492022
SANOFI US SERVICES INC.24$254,3092022
Chiesi USA, Inc.7$251,8462022
GLOBAL BLOOD THERAPEUTICS, INC.13$234,3302022
Clovis Oncology, Inc.11$196,7762022
VERTEX PHARMACEUTICALS INCORPORATED6$196,6932022
ALBIREO PHARMA, INC.21$193,3072022
Neurocrine BioSciences, Inc.69$185,6092022
Eisai Inc.13$179,4592022
Roche TCRC, Inc.12$163,1522022
United Therapeutics Corporation11$160,5602022
Horizon Therapeutics plc2$150,9082022
MED-EL Corporation3$147,5162022
Partner Therapeutics, Inc.1$145,7662022
Vanda Pharmaceuticals Inc.1$145,3502022
Biogen, Inc.6$145,1212022
Kite Pharma, Inc.9$145,0892022
Agios Pharmaceuticals, Inc.7$143,4092022
Medical Device Business Services, Inc.12$129,1652022
Shockwave Medical, Inc4$123,9932022

By nature of payment

NatureRecordsAmount
Research payment2,496$69,825,645
Grant89$1,733,392
Compensation for services other than consulting, including serving as faculty or as a speaker at a v90$543,019
Royalty or License28$503,291
Space rental or facility fees (teaching hospital only)121$372,754
Education90$345,483
Consulting Fee9$289,073
Charitable Contribution6$49,500
Debt forgiveness1$1,365
Long term medical supply or device loan1$350

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31Merck Sharp & Dohme LLC$2,617,491Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYEnhancing sensitivity to immune checkpoint and androgen receptor blockade in small cell neuroendocrine and intermediate 2022
2022-12-31Merck Sharp & Dohme LLC$989,964Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYImmunogenic Priming with PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer A Phase 1b Study of 177Lu-PSMA-612022
2022-12-31Merck Sharp & Dohme LLC$945,870Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA pilot study of pembrolizumab and liver-directed therapy for patients well-differentiated neuroendocrine tumors and sym2022
2022-12-31Merck Sharp & Dohme LLC$414,856Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Metastatic Colorectal Cancer2022
2022-12-31Merck Sharp & Dohme LLC$356,562Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Study of Neoadjuvant Pembrolizumab-Based Combination Therapy in Patients with Locally Advanced or Metastatic 2022
2022-12-31Merck Sharp & Dohme LLC$345,471Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Pilot Study of Pembrolizumab , an anti-PD programmed cell death-1 Antibody, in Combination with Carboplatin in Breast 2022
2022-12-31Merck Sharp & Dohme LLC$304,815Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase II Study of Checkpoint Inhibition with Anti-PD-1 Alone or Anti-PD-1 in Combination with Intratumoral Poly-ICLC The2022
2022-12-31Merck Sharp & Dohme LLC$261,903Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA phase II study of stereotactic radiosurgery in conjunction with the PD-1 inhibitor , pembrolizumab for the treatment o2022
2022-12-31Merck Sharp & Dohme LLC$219,351Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv2022
2022-12-31Merck Sharp & Dohme LLC$199,007Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYTesting the ability of MK-3475 to alter the tumor immune microenvironment of high grade, high risk DCIS2022
2022-12-31Merck Sharp & Dohme LLC$157,111Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer mCRPC with or w2022
2022-12-31Merck Sharp & Dohme LLC$95,370Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2022
2022-12-31Merck Sharp & Dohme LLC$89,012Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-342022
2022-12-31Merck Sharp & Dohme LLC$86,803Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2022
2022-12-31Merck Sharp & Dohme LLC$68,773Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che2022
2022-12-31Merck Sharp & Dohme LLC$64,129Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT2022
2022-12-31Merck Sharp & Dohme LLC$59,188Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N2022
2022-12-31Merck Sharp & Dohme LLC$58,645Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do2022
2022-12-31Merck Sharp & Dohme LLC$53,241Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYKEYMAKER U01 Master Study A Phase 2 Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab2022
2022-12-31Merck Sharp & Dohme LLC$51,713Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2022
2022-12-31Merck Sharp & Dohme LLC$48,474Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1,1b, Open label Clinical Study of Intratumoral,Intralesional Administration of V938 in Combination with Pembrol2022
2022-12-31Merck Sharp & Dohme LLC$39,096Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1 Open-Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for P2022
2022-12-31Merck Sharp & Dohme LLC$33,188Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2022
2022-12-31Merck Sharp & Dohme LLC$33,182Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASERandomized, Placebo-Controlled Trial to Evaluate the Safety of Letermovir PrevymisTM in Adults with Human Immunodeficien2022
2022-12-31Merck Sharp & Dohme LLC$31,168Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N2022
2022-12-31Merck Sharp & Dohme LLC$29,047Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671,V941 as a Monotherapy and in2022
2022-12-31AstraZeneca UK Limited$28,009Research paymentIn-kind items and servicesA Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants wit2022
2022-12-31Merck Sharp & Dohme LLC$24,623Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit2022
2022-12-31Merck Sharp & Dohme LLC$20,939Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit2022
2022-12-31Merck Sharp & Dohme LLC$18,452Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N2022
2022-12-31AstraZeneca Pharmaceuticals LP$17,904Research paymentIn-kind items and servicesCapivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292.2022
2022-12-31Siemens Medical Solutions USA, Inc.$14,470Research paymentIn-kind items and servicesBiograph mCT X-4R Device, MI - Nuclear Medicine (incl. PETNET & MIBR)Evaluation of myocardial uptake image quality in wholebody PET scans with OncoFreeze AI2022
2022-12-31Merck Sharp & Dohme LLC$13,985Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2022
2022-12-31Merck Sharp & Dohme LLC$13,562Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini2022
2022-12-31AstraZeneca Pharmaceuticals LP$13,398Research paymentIn-kind items and servicesTAGRISSO Drug, OncologyA Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with2022
2022-12-31Merck Sharp & Dohme LLC$13,353Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2022
2022-12-31Merck Sharp & Dohme LLC$12,744Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che2022
2022-12-31Merck Sharp & Dohme LLC$12,716Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Flourouracil in Subjects wi2022
2022-12-31AstraZeneca Pharmaceuticals LP$12,501Research paymentIn-kind items and servicesLOKELMA Drug, Cardiovascular and MetabolismNEUTRALIZE - Lokelma Metabolic Acidosis Study A double-blind randomized placebo-controlled parallel design multicenter p2022
2022-12-31Merck Sharp & Dohme LLC$10,636Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase 1b,2 study of immune and targeted combination therapies in participants with RCC2022
2022-12-31Merck Sharp & Dohme LLC$10,636Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B2022
2022-12-31Merck Sharp & Dohme LLC$10,339Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do2022
2022-12-31Merck Sharp & Dohme LLC$7,786Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial of Pembrolizumab MK-3475 in Subjects with Advanced,Unresectable or Metastatic Urothelial Cance2022
2022-12-31Merck Sharp & Dohme LLC$7,545Research paymentIn-kind items and servicesWELIREG Drug, ONCOLOGYAn Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin2022
2022-12-31Boston Scientific Corporation$6,766Research paymentCash or cash equivalentFarapulse Device, Structural HeartADVENT2022
2022-12-31Merck Sharp & Dohme LLC$6,655Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi2022
2022-12-31Merck Sharp & Dohme LLC$6,097Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis2022
2022-12-31Merck Sharp & Dohme LLC$6,070Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Two-Arm, Open-label, Randomized Phase III Study of Pembrolizumab MK-3475 monotherapy versus standard chemotherapy in P2022
2022-12-31Merck Sharp & Dohme LLC$5,873Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase 2b open-label, single-arm trial to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in2022
2022-12-31Merck Sharp & Dohme LLC$5,860Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv2022
2022-12-31AstraZeneca Pharmaceuticals LP$5,833Research paymentIn-kind items and servicesA PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATORS CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INO2022
2022-12-31Merck Sharp & Dohme LLC$5,641Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot2022
2022-12-31Merck Sharp & Dohme LLC$5,570Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial of Pembrolizumab MK-3475 in Subjects with Advanced,Unresectable or Metastatic Urothelial Cance2022
2022-12-31KARL STORZ Endoscopy-America$5,250EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2022
2022-12-31Merck Sharp & Dohme LLC$4,862Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2022
2022-12-31Merck Sharp & Dohme LLC$4,678Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2022
2022-12-31KARL STORZ Endoscopy-America$4,578EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$4,578EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$4,366Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Flourouracil in Subjects wi2022
2022-12-31KARL STORZ Endoscopy-America$4,344EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$4,344EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$4,249EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$4,246Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in Fi2022
2022-12-31Merck Sharp & Dohme LLC$4,209Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy f2022
2022-12-31Merck Sharp & Dohme LLC$4,195Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2022
2022-12-31Merck Sharp & Dohme LLC$4,193Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab MK-3475 in Locally Advanced,Metastatic Ren2022
2022-12-31Merck Sharp & Dohme LLC$3,994Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2022
2022-12-31Merck Sharp & Dohme LLC$3,967Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N2022
2022-12-31Merck Sharp & Dohme LLC$3,955Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A2022
2022-12-31Merck Sharp & Dohme LLC$3,850Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis2022
2022-12-31KARL STORZ Endoscopy-America$3,638EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2022
2022-12-31Merck Sharp & Dohme LLC$3,633Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT2022
2022-12-31Merck Sharp & Dohme LLC$3,582Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do2022
2022-12-31KARL STORZ Endoscopy-America$3,016EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$2,986Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial of Pembrolizumab MK-3475 in Subjects with Advanced,Unresectable or Metastatic Urothelial Cance2022
2022-12-31Merck Sharp & Dohme LLC$2,799Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-2242022
2022-12-31Merck Sharp & Dohme LLC$2,641Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot2022
2022-12-31Merck Sharp & Dohme LLC$2,632Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab MK-3475 in Locally Advanced,Metastatic Ren2022
2022-12-31Merck Sharp & Dohme LLC$2,523Research paymentIn-kind items and servicesZINPLAVA Biological, INFECTIOUS DISEASEProtocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar2022
2022-12-31Merck Sharp & Dohme LLC$2,503Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-2242022
2022-12-31Merck Sharp & Dohme LLC$2,408Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA phase II trial of MK3475 in Merkel Cell Carcinoma MCC2022
2022-12-31KARL STORZ Endoscopy-America$2,263EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2022
2022-12-31Merck Sharp & Dohme LLC$2,245Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck2022
2022-12-31KARL STORZ Endoscopy-America$2,179EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$2,047Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for 2022
2022-12-31Merck Sharp & Dohme LLC$2,032Research paymentIn-kind items and servicesZINPLAVA Biological, INFECTIOUS DISEASEProtocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar2022
2022-12-31KARL STORZ Endoscopy-America$2,022EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$1,923EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$1,836EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$1,374EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$1,308EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$1,229EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$921Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit2022
2022-12-31Merck Sharp & Dohme LLC$903Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Two-Arm, Open-label, Randomized Phase III Study of Pembrolizumab MK-3475 monotherapy versus standard chemotherapy in P2022
2022-12-31KARL STORZ Endoscopy-America$872EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$872EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$829EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$829EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$829EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$786Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Che2022
2022-12-31Merck Sharp & Dohme LLC$778Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy f2022
2022-12-31ABBVIE INC.$773Research paymentIn-kind items and servicesRST001 Phase I II Trial for Advanced Retinitis Pigmentosa2022
2022-12-31KARL STORZ Endoscopy-America$713EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$661Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinomas and Melanom2022
2022-12-31Abbott Laboratories$644Research paymentIn-kind items and services Device, Core Diagnostics2022
2022-12-31KARL STORZ Endoscopy-America$624EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31AstraZeneca Pharmaceuticals LP$554Research paymentIn-kind items and servicesA Modular Phase I IIa Open label Multi centre Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics 2022
2022-12-31KARL STORZ Endoscopy-America$544EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$544EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$472EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$472EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$472EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$472EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$442EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$442EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$430Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase 2b open-label, single-arm trial to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in2022
2022-12-31AstraZeneca Pharmaceuticals LP$395Research paymentIn-kind items and servicesIMFINZI Biological, OncologyThis is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus2022
2022-12-31KARL STORZ Endoscopy-America$387EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$347EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$347EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$340Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit2022
2022-12-31KARL STORZ Endoscopy-America$300EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$277EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$275EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$275EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$275EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31AstraZeneca UK Limited$270Research paymentIn-kind items and servicesA Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo2022
2022-12-31KARL STORZ Endoscopy-America$251EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$236EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$236EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$236EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$221Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus 2022
2022-12-31Merck Sharp & Dohme LLC$221Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase II Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectab2022
2022-12-31KARL STORZ Endoscopy-America$161EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$161EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$157EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$125EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$112EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$112EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$112EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31KARL STORZ Endoscopy-America$111EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$90Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with 2022
2022-12-31Merck Sharp & Dohme LLC$70Research paymentIn-kind items and services Biological, VACCINEA Study to Evaluate the Efficacy of GARDASILTM in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related External Ge2022
2022-12-31KARL STORZ Endoscopy-America$66EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31ABBVIE INC.$63Research paymentIn-kind items and servicesA Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate 2022
2022-12-31Merck Sharp & Dohme LLC$62Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase II Clinical Trial of Pembrolizumab MK-3475 as Monotherapy for Metastatic Triple Negative Breast Cancer mTNBC K2022
2022-12-31KARL STORZ Endoscopy-America$57EducationIn-kind items and servicesCLICKLINE Device, LAPAROSCOPY2022
2022-12-31KARL STORZ Endoscopy-America$57EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Abbott Laboratories$33Research paymentIn-kind items and services Device, Core Diagnostics2022
2022-12-31KARL STORZ Endoscopy-America$17EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2022
2022-12-31Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2022
2022-12-31Merck Sharp & Dohme LLC$2Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase 1b,2 study of immune and targeted combination therapies in participants with RCC2022
2022-12-31Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYKEYMAKER U01Substudy 1 A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combi2022
2022-12-31Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B2022
2022-12-30Merck Sharp & Dohme LLC$60,920Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv2022
2022-12-30Janssen Research & Development, LLC$43,932Research paymentCash or cash equivalentDARZALEX Drug, OncologyA Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D2022
2022-12-30Janssen Research & Development, LLC$14,659Research paymentCash or cash equivalentA Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t2022
2022-12-29PUMA BIOTECHNOLOGY, INC.$19,686Research paymentCash or cash equivalentNERLYNX Drug, ONCOLOGYAN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEP2022
2022-12-29PFIZER INC.$15,400Research paymentCash or cash equivalentXTANDI Drug, ONCOLOGYA RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA2022
2022-12-29Abbott Laboratories$4,174Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentARCHITECT Device, Core Diagnostics2022
2022-12-28BioMarin Pharmaceutical Inc.$452,776Research paymentCash or cash equivalentSingle-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients2022
2022-12-28United Therapeutics Corporation$18,123Research paymentCash or cash equivalentTYVASO Drug, PAHA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2022
2022-12-28United Therapeutics Corporation$15,000GrantCash or cash equivalent2022
2022-12-28Roche TCRC, Inc.$2,064Research paymentCash or cash equivalent DrugPHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS2022
2022-12-28Roche TCRC, Inc.$560Research paymentCash or cash equivalent DrugPHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS2022
2022-12-27Genentech, Inc.$116,708Research paymentCash or cash equivalent Drug2022
2022-12-27Genentech, Inc.$23,130Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyASSESSING DISEASE ACTIVITY IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS USING OCRELIZUMAB2022
2022-12-27Janssen Research & Development, LLC$19,606Research paymentCash or cash equivalentTREMFYA Drug, ImmunologyImmunogenetic Profiling Of Guselkumab For The Treatment Of Plaque And Guttate Psoriasis2022
2022-12-27Haemonetics Corporation$19,150Research paymentCash or cash equivalentTEG6S HEMOSTASIS SYSTEM Device, DEVICESAN OBSERVATIONAL TRIAL TO ASSESS THE PERFORMANCE OF THE TEG 6S DIAGNOSTIC SYSTEM WITH THE CITRATED K KH RTH FFH CARTR2022
2022-12-27Roche Products Limited$7,172Research paymentCash or cash equivalentEsbriet Biological, ImmunologyPH III OLE TRIAL TO EVALUATE LONG TERM SAFETY AND EFFICACY OF PRM 151 IN PATIENTS WITH IPF2022
2022-12-26Janssen Research & Development, LLC$48,109Research paymentCash or cash equivalentTECVAYLI Biological, OncologyA Multiarm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma2022
2022-12-23Aadi Bioscience, Inc.$22,605Research paymentCash or cash equivalentABI-009A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid T2022
2022-12-22Genentech, Inc.$240,834Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyIMPACT2022
2022-12-22Ultragenyx Pharmaceutical Inc.$21,492Research paymentCash or cash equivalentCrysvita Drug, XLH Metabolic Bone DisorderUX023-CL4012022
2022-12-22Janssen Research & Development, LLC$18,016Research paymentCash or cash equivalentA Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj2022
2022-12-22ALBIREO PHARMA, INC.$16,892Research paymentCash or cash equivalentBylvay Drug, GastroenterologyAn Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro2022
2022-12-22AstraZeneca Pharmaceuticals LP$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentANDEXXA Biological, Rare Disease2022
2022-12-22Bio-Rad Laboratories, Inc.$2,739Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLiquichek Device, Controls2022
2022-12-22SEAGEN INC.$2,314Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous2022
2022-12-22SEAGEN INC.$2,186Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous2022
2022-12-22SEAGEN INC.$2,186Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous2022
2022-12-22SEAGEN INC.$2,186Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous2022
2022-12-22SEAGEN INC.$2,186Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous2022
2022-12-22SEAGEN INC.$2,186Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous2022
2022-12-22SEAGEN INC.$2,186Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous2022
2022-12-22SEAGEN INC.$2,186Research paymentCash or cash equivalentTUKYSA Drug, OncologyA Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previous2022
2022-12-22Bio-Rad Laboratories, Inc.$330Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLiquichek Device, Controls2022
2022-12-21Neurocrine BioSciences, Inc.$11,037Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in 2022
2022-12-21Exelixis Inc.$10,000Royalty or LicenseCash or cash equivalent2022
2022-12-21Kite Pharma, Inc.$9,064Research paymentCash or cash equivalentA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory 2022
2022-12-21BioMarin Pharmaceutical Inc.$6,322Research paymentCash or cash equivalentAn Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia2022
2022-12-21Sunovion Pharmaceuticals Inc.$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-12-21PFIZER INC.$3,861Research paymentCash or cash equivalentPHASE 3 OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF07055480 RECOMBINANT AAV26 HUMAN FACTOR VIII 2022
2022-12-21Olympus America Inc.$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentRICHARDS SINUSCOPE ADAPTOR FOR LIGHT CABLE Device, Ear, Nose, Throat2022
2022-12-21Neurocrine BioSciences, Inc.$3,234Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN 2022
2022-12-21Medical Device Business Services, Inc.$3,000GrantCash or cash equivalent2022
2022-12-21Gilead Sciences, Inc.$1,557Research paymentCash or cash equivalentVemlidy Drug, HBVA Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala2022
2022-12-21Celgene Corporation$1,477Research paymentCash or cash equivalentPhase IIIB Reblozyl Rollover - A Phase 3b, open label, single-arm rollover study to evaluate long term safety in subject2022
2022-12-21Neurocrine BioSciences, Inc.$1,388Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRINECERFONT (NBI-74788) IN 2022
2022-12-21Neurocrine BioSciences, Inc.$664Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in 2022

The latest 200 records of 2,931.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.